Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

US Patent 11965031 · Granted Apr 23, 2024

Estimated economic value: $129,563,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of glutamate modulating agents with immunotherapies to treat cancer2025
Use of riluzole oral disintegrating tablets for treating diseases2025
Agonistic antibodies that bind human CD40 and uses thereof2025
Use of riluzole prodrugs to treat Alzheimer's disease2025
Use of riluzole prodrugs to treat alzheimer's disease2024
Sublingual formulation of riluzole2024
Use of riluzole prodrugs to treat ataxias2024
Sublingual formulation of riluzole2023
Glutamate agents in the treatment of mental disorders2023
Chimeric antigen receptors targeting TIM-12023
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs2022
Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to t2022